Results 101 to 110 of about 111,950 (304)

Engineered Allosteric Biosensor for In Situ DNA Glycosylase Detection in Neuroblastoma Risk Stratification and Drug Resistance Monitoring

Advanced Science, EarlyView.
An engineered allosteric biosensor (UUU‐DZ‐tFNA) was developed, in which UDG specifically recognizes and activates a DNAzyme to achieve signal cycle amplification in a sequentially activatable mode. UUU‐DZ‐tFNA achieves in situ UDG detection across multiple biological levels and facilitates risk stratification and drug resistance monitoring of NB ...
Yaqing Lu, Yingyu Zhang, Xianwei Zhang, Mengxin Zhang, Fei Zhang, Jushan Sun, Yahui Yang, Kangbo Liu, Peng Wang, Shuying Luo, Wancun Zhang   +10 more
wiley   +1 more source

Overview of History and Progress in BRCA1 Research: The First BRCA1 Decade [PDF]

Cancer Biology & Therapy, 2004
The BRCA1 protein presents a paradox to the scientists investigating its link to cancer. BRCA1 provides a function essential to all cell types, but its mutation is only associated with a subset of cancers including breast and ovarian cancers. The priorities of BRCA1 research are the identification of the function of BRCA1, which is required in all ...
openaire   +2 more sources

Disentangling Heterogeneous Molecular Networks for Multi‐Omics‐Driven Cancer Driver Discovery

Advanced Science, EarlyView.
DRIVE integrates PPI topology and pan‐cancer multi‐omics profiles through dual‐view graph disentanglement, contrastive representation learning, and joint optimization. Across six PPI networks, DRIVE outperforms ten baselines and remains robust to structural and annotation perturbations.
Xinjing Gong, Ji Li, Mu Su, Peishen Yu, Te Ma, Ruiyang Zhai, Chenye Zhang, Mengyan Zhang, Yan Zhang   +8 more
wiley   +1 more source

A family history of breast cancer will not predict female early onset breast cancer in a population-based setting [PDF]

, 2008
: BACKGROUND: An increased risk of breast cancer for relatives of breast cancer patients has been demonstrated in many studies, and having a relative diagnosed with breast cancer at an early age is an indication for breast cancer screening.
de Bock, Geertruida H.; id_orcid, Seynaeve, C., Krol-Warmerdam Elly MM, Blom Jannet, de Bock, G.H., Cornelisse, C.J., Blom, Jannet, de Bock, GH, Brekelmans, C.T., Asperen, C.J. (Christi) van, Klijn, J.G., Jacobi, Catharina E., Houwelingen, J.C. van, van Asperen Christi J, Krol-Warmerdam, Elly M. M., Devilee, P, Brekelmans, C.T. (Cecile), Brekelmans Cecile TM, Klijn, Jan G. M., de Bock Geertruida H, Krol-Warmerdam, E.M., Krol-Warmerdam, EMM, van Asperen, C.J., Blom, J. (Jannet), Cornelisse Cees J, Jacobi, C.E., Tollenaar Rob AEM, Cornelisse, Cees J., Krol-Warmerdam, E.M.M. (Elly), Tollenaar, R.A., Seynaeve, C.M. (Caroline), Jacobi, CE, Tollenaar, R.A.E.M. (Rob), de Bock, Geertruida H., Blom, J., van Houwelingen, JC, Tollenaar, Rob A. E. M., van Asperen, Christi J., Brekelmans, CTM (Cecile), Bock, G.H. (Geertruida) de, van Asperen, CJ, Klijn Jan GM, van Houwelingen Johannes C, Devilee, Peter, Seynaeve Caroline, Brekelmans, Cecile T. M., Seynaeve, Caroline, Devilee Peter, Klijn, J.G.M. (Jan), Jacobi Catharina E, van Houwelingen, J.C., Klijn, Jan, Jacobi, C.E. (Catharina), Devilee, P. (Peter), Tollenaar, RAEM, Devilee, P., Cornelisse, C.J. (Cees), van Houwelingen, Johannes C., Blom, J, Cornelisse, CJ   +59 more
core   +2 more sources

Identification of senescence‐related genes in Parkinson's disease reveals candidate therapeutic targets and pathological processes

Animal Models and Experimental Medicine, EarlyView.
At the genomic level, a large number of differentially expressed genes (DEGs) and aging‐related DEGs have been screened. Ten hub genes, such as IFNγ and IRF7, have been identified and shown potential value in the diagnosis of PD, holding promise as novel biomarkers to facilitate early and precise diagnosis.
Haojie Wu, Tingting Liu, Xiangshu Cheng, Jianshe Wei   +3 more
wiley   +1 more source

BRCA1 polymorphisms [PDF]

British Journal of Cancer, 1997
Campbell, IG, Schroff, R, Englefield, P, Eccles, DM   +3 more
openaire   +3 more sources

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub, Armin Sepp, Amin Rostami‐Hodjegan, Brahim Achour   +3 more
wiley   +1 more source

Efficacy of Next-Generation Sequencing in Identifying Genetic Markers for Prostate Cancer Risk

Journal of Pharmacy and Bioallied Sciences
Background: Prostate cancer is one of the most prevalent cancers among men worldwide. The identification of genetic markers that contribute to the risk of prostate cancer can significantly enhance early diagnosis and personalized treatment strategies ...
Fahad H. Alaithan, Raghad H. Alaithan, Tauheed Ahmed   +2 more
doaj   +1 more source

BRCA1- and BRCA2-deficient mES cells are hypersensitive to olaparib and veliparib but not BSI-201.

, 2016
The clonogenic survival assays of wild-type, Brca1-/- 236.44 and Brca2lex1/lex2 mES cells following treatment with olaparib, veliparib and BSI-201. BRCA1- and BRCA2-deficient cells were extremely sensitive to olaparib and veliparib as compared to wild ...
Shuhei Ito (3151281), Mary Ellen Moynahan (111580), Maria Jasin (47165), Conleth G. Murphy (3151284), Ekaterina Doubrovina (3151287)   +4 more
core   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source